Sangart Inc., the San Diego-based biopharmaceutical company, today lodged its planning application for a new manufacturing facility at the IDA Industrial Estate, Carrigtwohill, Co. Cork.
“We are delighted that our planning application has now been formally submitted to Cork County Council. It’s a significant milestone for the project team and we very much look forward to progressing our exciting plans in partnership with our project management team and other key stakeholders”, said Dr. Walter Matzmorr, Vice-President, Operations Ireland, Sangart.
Engineering, procurement and construction management work began on Sangart’s 10,300 sq.m. (approximately 110,000 sq.ft.) facility in July. Subject to a successful planning outcome, the project is expected to create up to 125 jobs during construction, with employment for up to 200 people once completed.
Sangart recently appointed Jacobs Engineering to perform the engineering, procurement and construction management for its new manufacturing facility. Cork-based DPS Engineering were selected to perform the commissioning and qualification work for the new facility. The integrated project team will consist of Jacobs Engineering, DPS Engineering and engineers and process experts from Sangart’s headquarters in San Diego, California. Sangart has also engaged the services of Franklin & Andrews to support the project team as cost and contract advisors.
Sangart expects to break ground on-site in Carrigtwohill towards the end of Q1 2013, with the facility due to be mechanically complete by Q2 2014. Start up and product validation is targeted for 2015.
Founded in San Diego in 1998, Sangart is a global biopharmaceutical company dedicated to developing and commercialising ischemic rescue therapies. Sangart’s product platform is based on the MP4 molecule, a gas-delivery platform designed to help patients in crisis with medical conditions that cause ischemia (oxygen deprivation of tissues) and organ dysfunction such as hemorrhagic shock and sickle cell disease.
Sangart Ireland will serve as the company’s European headquarters and the European sales and manufacturing base for its MP4OX and MP4CO therapies for haemorraghic shock and Sickle Cell Disease.